Affinage

EXOSC1

Exosome complex component CSL4 · UniProt Q9Y3B2

Length
195 aa
Mass
21.5 kDa
Annotated
2026-06-09
49 papers in source corpus 17 papers cited in narrative 18 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

EXOSC1 (hCsl4p/Csl4p) is a structural cap subunit of the RNA exosome, the conserved 3'-to-5' RNA-degradation machine, where it sits atop the hexameric RNase-PH ring and helps form the RNA-binding cap that channels substrate through the central pore for processive degradation (PMID:16285927, PMID:17380186). In human cells it incorporates into the exosome through direct protein-protein interactions with the EXOSC6 (hRrp42p) and EXOSC7 (hRrp46p) subunits, and mutants unable to bind these partners fail to associate with the complex (PMID:11812149); EXOSC1 is required for stable assembly of the nine-subunit EXO9 complex (PMID:33463720). EXOSC1 is itself catalytically inert but contributes substrate specificity and binding: its zinc-ribbon and S1 RNA-binding domains are required for exosome-mediated mRNA decay yet are dispensable for rRNA/snRNA processing and viability, genetically separating distinct exosome functions, and cap-conferred substrate binding promotes degradation of structured RNAs and transcripts with particular 3'-end composition (PMID:11027292, PMID:19060898, PMID:19053279, PMID:20488184). Human EXOSC1 functionally substitutes for yeast Csl4p and physically interacts with the catalytic Dis3p exonuclease (PMID:22068837). CARM1-mediated methylation of arginine 6 protects EXOSC1 from proteasomal degradation, thereby enhancing exosome activity and suppressing the viral-mimicry response by limiting nuclear export of retroelement transcripts (PMID:40203080). Loss-of-function variants cause pontocerebellar hypoplasia type 1 by reducing EXOSC1 protein and EXO9 complex abundance (PMID:33463720, PMID:37024942), and Exosc1-null mouse embryos fail to initiate gastrulation, establishing an essential developmental role (PMID:37940010). A reported in vitro single-stranded DNA cleavage activity links EXOSC1 to C>A mutational signatures in renal carcinoma cells (PMID:34159897).

Mechanistic history

Synthesis pass · year-by-year structured walk · 11 steps
  1. 2000 High

    Established that the exosome cap subunit Csl4p carries a function-specific RNA-binding domain, separating mRNA degradation from rRNA/snRNA processing.

    Evidence Genetic epistasis and a point mutation (ski4-1, G253E) with mRNA half-life and RNA processing assays in S. cerevisiae

    PMID:11027292

    Open questions at the time
    • Did not define the structural basis of the RNA-binding domain
    • Human ortholog not yet characterized
  2. 2001 Medium

    Identified the human ortholog hCsl4p as a bona fide component of the human exosome (PM/Scl complex).

    Evidence ELISA and Western blotting of recombinant hCsl4p with patient autoimmune sera

    PMID:11879549

    Open questions at the time
    • Autoantibody recognition does not define molecular function
    • No interaction map within the complex
  3. 2002 High

    Defined how EXOSC1 anchors into the exosome, showing direct interactions with EXOSC6 (hRrp42p) and EXOSC7 (hRrp46p) are required for incorporation.

    Evidence Mammalian two-hybrid, GST pull-down, and co-IP with loss-of-function mutants

    PMID:11812149

    Open questions at the time
    • Did not resolve assembly order relative to other subunits
    • No structural model of the human interface
  4. 2007 High

    Resolved the structural role of Csl4 as part of a trimeric cap forming an RNA entry pore that channels substrate to the catalytic core for processive degradation.

    Evidence X-ray crystallography of archaeal exosome with and without bound RNA

    PMID:16285927 PMID:17380186

    Open questions at the time
    • Archaeal system; human-specific contacts not directly resolved
    • Does not address cofactor-dependent structured-RNA handling in vivo
  5. 2010 High

    Demonstrated that Csl4 confers distinct substrate selectivity and recruits the archaea-specific DnaG, showing the cap is a modular determinant of specificity rather than a passive scaffold.

    Evidence In vitro reconstitution of archaeal exosomes with defined caps, comparative RNA degradation and binding assays

    PMID:19053279 PMID:20488184 PMID:23324612 PMID:24789718

    Open questions at the time
    • DnaG is archaea-specific; no human cap-specific cofactor identified
    • Csl4 itself has no catalytic activity
  6. 2011 High

    Confirmed functional conservation by showing human hCsl4p rescues yeast ski4 loss and interacts with the Dis3p catalytic exonuclease.

    Evidence Yeast complementation, superkiller phenotype analysis, co-IP with Dis3p, site-directed mutagenesis

    PMID:22068837

    Open questions at the time
    • N-terminal third dispensable but its native role unclear
    • Human in-cell substrate specificity not mapped
  7. 2021 Medium

    Linked EXOSC1 to human disease by showing a missense variant reduces EXOSC1 and EXO9 complex abundance and causes pontocerebellar hypoplasia type 1.

    Evidence Exome sequencing, immunoblotting, blue native PAGE on patient cells

    PMID:33463720

    Open questions at the time
    • Tissue-specific basis of neurodegeneration not explained
    • No rescue experiment in patient cells
  8. 2021 Medium

    Reported a non-canonical activity, proposing EXOSC1 cleaves ssDNA at C sites and contributes to C>A mutagenesis and PARP-inhibitor sensitivity in renal carcinoma.

    Evidence In vitro ssDNA cleavage assays plus mutation-spectrum correlation and cell sensitivity assays in KIRC

    PMID:34159897

    Open questions at the time
    • Novel ssDNA-cleavage activity not independently replicated
    • Mechanistic link between exosome role and DNA cleavage unresolved
  9. 2023 Medium

    Validated pathogenicity of EXOSC1 variants and tied disease to reduced protein stability and impaired exosome function.

    Evidence Yeast complementation/growth assays and Western blotting of human variants in budding yeast; knockout mouse embryo phenotyping

    PMID:37024942 PMID:37940010

    Open questions at the time
    • Cross-species variant modeling may not capture human-specific effects
    • Molecular cause of gastrulation failure not defined; no rescue performed
  10. 2025 Medium

    Identified CARM1-mediated arginine-6 methylation as a stabilizing post-translational switch controlling EXOSC1 abundance, exosome activity, and the viral-mimicry/antitumor immune response.

    Evidence Mass spectrometry, proteasome inhibitor assays, RNAseq and pathway analysis in tumor cell lines

    PMID:40203080

    Open questions at the time
    • Single lab; physiological generality beyond tumor cells unclear
    • How methylation alters complex stability mechanistically not resolved
  11. 2025 Medium

    Placed EXOSC1 as the terminally incorporated cap subunit in a sequential exosome assembly hierarchy and showed it is dispensable for viability, revealing modular, resilient architecture.

    Evidence Inducible dual-guide CRISPR/Cas9 knockouts and proteomics in mouse embryonic stem cells (preprint)

    PMID:bio_10.1101_2025.03.14.643291

    Open questions at the time
    • Preprint, not peer-reviewed
    • Dispensability for viability contrasts with embryonic lethality in vivo; reconciliation needed

Open questions

Synthesis pass · forward-looking unresolved questions
  • How EXOSC1's cap-mediated substrate selectivity and its proposed ssDNA-cleavage activity are integrated, regulated, and deployed across tissues to produce the human disease and developmental phenotypes remains unresolved.
  • No human-cell structural model of the assembled cap with EXOSC1
  • Substrate repertoire degraded via EXOSC1 in human cells undefined
  • Reconciliation of in vitro dispensability with embryonic essentiality

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0003723 RNA binding 5 GO:0005198 structural molecule activity 4 GO:0060089 molecular transducer activity 2
Pathway
R-HSA-8953854 Metabolism of RNA 4 R-HSA-1266738 Developmental Biology 1
Complex memberships
RNA exosome (EXO9 / PM-Scl complex)

Evidence

Reading pass · 18 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2000 The SKI4 gene is identical to CSL4, which encodes a core component of the exosome. A point mutation in the putative RNA-binding domain of Csl4p (ski4-1, G253E) strongly impairs 3'-to-5' mRNA degradation without affecting exosome function in rRNA or snRNA processing, demonstrating that distinct exosome functions can be genetically separated and that the RNA-binding domain of Csl4p has a specific role in mRNA degradation. Genetic epistasis, allele identification, mRNA half-life assays, RNA processing assays in S. cerevisiae Molecular and cellular biology High 11027292
2001 The human protein hCsl4p is a component of the human exosome (PM/Scl complex), as evidenced by autoantibodies in patients with idiopathic inflammatory myopathy and PM/Scl overlap syndrome targeting hCsl4p along with other exosome subunits. ELISA and Western blotting with affinity-purified recombinant hCsl4p using patient sera Arthritis research Medium 11879549
2002 Human hCsl4p directly interacts with exosome subunits hRrp42p and hRrp46p, and these protein-protein interactions are required for hCsl4p's association with the exosome complex in vivo. Mutants of hCsl4p that fail to interact with either hRrp42p or hRrp46p cannot associate with the exosome. Mammalian two-hybrid assay, GST pull-down, co-immunoprecipitation from cell lysates Journal of molecular biology High 11812149
2005 Crystal structures of archaeal exosome isoforms revealed that Csl4 (along with Rrp4) forms a trimeric cap on top of the hexameric RNase-PH domain ring. The S1 domains of this cap and a 'neck' region of the RNase-PH ring form an RNA entry pore that restricts access to unstructured RNA, explaining processive degradation of unstructured RNA and the requirement for cofactors to degrade structured RNA. X-ray crystallography of archaeal exosome, tungstate soaks, structural and mutational analysis Molecular cell High 16285927
2007 Crystal structure of the Sulfolobus solfataricus nine-subunit exosome with bound RNA substrate shows that RNA binds both at the active site and at the opposite side in the narrowest constriction of the central channel, establishing that Csl4 contributes to the RNA-binding cap that channels substrate through the central pore for processive degradation. X-ray crystallography at 1.6 Å and 2.3 Å resolution with RNA-bound complex EMBO reports High 17380186
2008 In yeast (Csl4/Ski4p), the zinc-ribbon domain of Csl4 is required for exosome-mediated mRNA decay but none of its domains are individually required for viability, indicating that specific structural domains contribute to specific exosome functions. Domain deletion analysis in S. cerevisiae with mRNA decay assays Nature structural & molecular biology High 19060898
2008 Archaeal Csl4, when incorporated into the nine-subunit exosome (Csl4-exosome), enhances efficient degradation of structured RNA substrates (tRNA, heteropolymeric transcripts) by the catalytic Rrp41-Rrp42 hexamer. Csl4 itself has no hydrolytic RNase activity alone or in context of the complex, but strong substrate binding mediated by Csl4 is important for phosphorolysis. In vitro reconstitution of archaeal exosome complexes with different subunit compositions, RNase activity assays under varied conditions Biochemistry High 19053279
2010 Archaeal Csl4 confers different substrate specificity to the exosome compared with Rrp4: the Csl4-exosome degrades RNA with an A-poor 3'-end with higher efficiency, while the Rrp4-exosome strongly prefers poly(A) RNA. This establishes that Csl4 and Rrp4 have distinct functional roles in substrate selection. In vitro RNA degradation assays with reconstituted archaeal exosome complexes containing defined Rrp4 or Csl4 caps FEBS letters High 20488184
2010 The Csl4-exosome (archaeal) interacts with the archaea-specific DnaG subunit, which binds to the Csl4-exosome but not to the Rrp4-exosome, showing that Csl4 mediates DnaG recruitment to the exosome complex. In vitro binding assays with reconstituted complexes; co-purification FEBS letters Medium 20488184
2011 Human hCsl4p functionally rescues the null phenotype of yeast ski4Δ cells and partially complements the superkiller phenotype of ski4-1 mutation. The equivalent point mutation G152E in hCsl4p (corresponding to yeast ski4-1 G253E) impairs hCsl4p activity. hCsl4p physically interacts with the Dis3p exonuclease of the yeast exosome despite lacking the N-terminal third of Ski4p. This N-terminal third of Ski4p is dispensable for RNA degradation function. Yeast complementation assays, superkiller phenotype analysis, co-immunoprecipitation with Dis3p, site-directed mutagenesis Yeast High 22068837
2013 The archaeal DnaG protein binds to the Csl4-exosome but not to the Rrp4-exosome of Sulfolobus solfataricus. DnaG is a poly(A)-binding protein that enhances degradation of adenine-rich transcripts specifically in the context of the Csl4-exosome, functioning as a second poly(A)-binding subunit in the heteromeric RNA-binding cap. In vitro binding assays, RNA degradation assays with reconstituted exosome complexes, poly(A)-binding assays RNA biology Medium 23324612
2014 Archaeal Csl4 is involved in the interaction with the archaea-specific DnaG subunit of the exosome complex. In the archaeal exosome, Rrp4 confers poly(A) specificity while Csl4 mediates DnaG association. Both Rrp4 and Csl4 form a variable RNA-binding trimeric cap on the hexameric ring. Biochemical reconstitution, subunit interaction analysis, in vitro RNA degradation assays Wiley interdisciplinary reviews. RNA Medium 24789718
2021 A homozygous missense variant p.Ser35Leu in EXOSC1 reduces EXOSC1 protein levels and reduces the EXO9 (nine-subunit exosome) complex abundance in patient cells, establishing that EXOSC1 is required for stable EXO9 complex formation in human cells and that loss of EXOSC1 function causes pontocerebellar hypoplasia type 1. Immunoblotting, blue native PAGE, exome sequencing, in silico mutagenesis of protein structure Clinical genetics Medium 33463720
2021 EXOSC1 cleaves single-stranded DNA preferentially at C sites in vitro, acts as an endogenous source of mutations via C>A transversions in human kidney renal clear cell carcinoma cells, and sensitizes these cells to PARP inhibitors. In vitro ssDNA cleavage assays, statistical correlation of EXOSC1 expression with mutation spectra in KIRC, cell sensitivity assays with PARP inhibitors eLife Medium 34159897
2023 The EXOSC1 variant p.Arg183Trp causes a slow-growth phenotype in yeast when expressed as the human variant, while EXOSC1-Ser35Leu is lethal in the same model, demonstrating impaired exosome function. Protein levels of both EXOSC1 variants are reduced compared with wild-type when expressed in budding yeast, confirming pathogenicity through reduced protein stability. Yeast complementation and growth assays, Western blotting for protein levels in yeast American journal of medical genetics. Part A Medium 37024942
2023 Exosc1 null mouse embryos implant and form an egg cylinder but are developmentally delayed and fail to initiate gastrulation by embryonic day 7.5, demonstrating that EXOSC1 is essential for early mammalian development at the gastrulation stage. Homozygous knockout mouse embryo analysis, embryo recovery at defined developmental stages, morphological and lineage-specification analysis Gene expression patterns Medium 37940010
2025 CARM1 methylates arginine 6 of EXOSC1, protecting it from proteasome-mediated degradation. This post-translational methylation event enhances RNA exosome activity, attenuates nuclear export of retroelement transcripts by the mRNA export pathway, and thereby suppresses the viral mimicry response and antitumor immunity. Mass spectrometry identification of methylation site, proteasome inhibitor assays, RNAseq, functional pathway analysis in tumor cell lines Science translational medicine Medium 40203080
2025 Using inducible CRISPR/Cas9 knockouts in mouse embryonic stem cells, Exosc1 is identified as the terminally incorporated cap subunit in a sequential RNA exosome assembly pathway (initiated by Exosc2, Exosc4, and Exosc7). Unlike other structural subunits, Exosc1 is dispensable for cell viability, revealing that the RNA exosome has a modular, functionally resilient architecture. Orphan exosome subunits are degraded by the ubiquitin-proteasome system. Inducible dual-guide CRISPR/Cas9 knockout system in mESCs, proteomics, assembly hierarchy analysis bioRxivpreprint Medium bio_10.1101_2025.03.14.643291

Source papers

Stage 0 corpus · 49 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2008 The exosome contains domains with specific endoribonuclease, exoribonuclease and cytoplasmic mRNA decay activities. Nature structural & molecular biology 241 19060898
2012 Transcriptome-wide analysis of exosome targets. Molecular cell 164 23000172
2000 Function of the ski4p (Csl4p) and Ski7p proteins in 3'-to-5' degradation of mRNA. Molecular and cellular biology 154 11027292
2000 The yeast antiviral proteins Ski2p, Ski3p, and Ski8p exist as a complex in vivo. RNA (New York, N.Y.) 142 10744028
2005 Structural framework for the mechanism of archaeal exosomes in RNA processing. Molecular cell 141 16285927
1978 Chromosomal superkiller mutants of Saccharomyces cerevisiae. Journal of bacteriology 131 363683
1984 Superkiller mutations in Saccharomyces cerevisiae suppress exclusion of M2 double-stranded RNA by L-A-HN and confer cold sensitivity in the presence of M and L-A-HN. Molecular and cellular biology 122 6371496
2003 An exosome-like complex in Sulfolobus solfataricus. EMBO reports 118 12947419
2007 RNA channelling by the archaeal exosome. EMBO reports 99 17380186
2001 Autoantibodies directed to novel components of the PM/Scl complex, the human exosome. Arthritis research 72 11879549
2003 A role for the exosome in the in vivo degradation of unstable mRNAs. RNA (New York, N.Y.) 61 14624005
1989 Structure and nuclear localization signal of the SKI3 antiviral protein of Saccharomyces cerevisiae. Yeast (Chichester, England) 52 2660461
2006 Characterization of native and reconstituted exosome complexes from the hyperthermophilic archaeon Sulfolobus solfataricus. Molecular microbiology 46 17078816
1998 Mutations synthetically lethal with cep1 target S. cerevisiae kinetochore components. Genetics 43 9584087
1988 Expression of the rpl23, rpl2 and rps19 genes in spinach chloroplasts. Nucleic acids research 43 3362671
2017 Transcriptome-wide analysis of alternative routes for RNA substrates into the exosome complex. PLoS genetics 36 28355211
2002 Protein-protein interactions of hCsl4p with other human exosome subunits. Journal of molecular biology 32 11812149
2014 Structure and function of the archaeal exosome. Wiley interdisciplinary reviews. RNA 30 24789718
1979 A mutant killer plasmid whose replication depends on a chromosomal "superkiller" mutation. Genetics 27 17248905
2021 Bi-allelic missense variant, p.Ser35Leu in EXOSC1 is associated with pontocerebellar hypoplasia. Clinical genetics 25 33463720
2020 RNA exosome mutations in pontocerebellar hypoplasia alter ribosome biogenesis and p53 levels. Life science alliance 25 32527837
2016 High-specificity bioinformatics framework for epigenomic profiling of discordant twins reveals specific and shared markers for ACPA and ACPA-positive rheumatoid arthritis. Genome medicine 25 27876072
2013 A prototypic lysine methyltransferase 4 from archaea with degenerate sequence specificity methylates chromatin proteins Sul7d and Cren7 in different patterns. The Journal of biological chemistry 25 23530048
2008 Rrp4 and Csl4 are needed for efficient degradation but not for polyadenylation of synthetic and natural RNA by the archaeal exosome. Biochemistry 25 19053279
2012 Heterogeneous complexes of the RNA exosome in Sulfolobus solfataricus. Biochimie 22 22503705
2010 The evolutionarily conserved subunits Rrp4 and Csl4 confer different substrate specificities to the archaeal exosome. FEBS letters 22 20488184
2010 Quantitative analysis of processive RNA degradation by the archaeal RNA exosome. Nucleic acids research 19 20392821
2019 The RNA degradation pathway is involved in PPARα-modulated anti-oral tumorigenesis. BioMedicine 15 31724941
2018 Inhibition of pancreatic cancer Panc1 cell migration by omeprazole is dependent on aryl hydrocarbon receptor activation of JNK. Biochemical and biophysical research communications 15 29758193
2010 The archaeal exosome localizes to the membrane. FEBS letters 15 20488181
2014 Archaeal DnaG contains a conserved N-terminal RNA-binding domain and enables tailing of rRNA by the exosome. Nucleic acids research 14 25326320
2021 Exosome component 1 cleaves single-stranded DNA and sensitizes human kidney renal clear cell carcinoma cells to poly(ADP-ribose) polymerase inhibitor. eLife 12 34159897
2013 The archaeal DnaG protein needs Csl4 for binding to the exosome and enhances its interaction with adenine-rich RNAs. RNA biology 11 23324612
2023 Harnessing endogenous transcription factors directly by small molecules for chemically induced pluripotency inception. Proceedings of the National Academy of Sciences of the United States of America 9 37192170
2023 Pontocerebellar hypoplasia associated with p.Arg183Trp homozygous variant in EXOSC1 gene: A case report. American journal of medical genetics. Part A 7 37024942
2011 The archaeal exosome. Advances in experimental medicine and biology 7 21713675
2022 A Novel Layer 4 Corticofugal Cell Type/Projection Involved in Thalamo-Cortico-Striatal Sensory Processing. The Journal of neuroscience : the official journal of the Society for Neuroscience 6 34983816
2021 Identification of an miRNA Regulatory Network and Candidate Markers for Ischemic Stroke Related to Diabetes. International journal of general medicine 6 34262334
2017 Nop5 interacts with the archaeal RNA exosome. FEBS letters 6 29159940
2016 cDNA-library testing identifies transforming genes cooperating with c-myc in mouse pre-B cells. European journal of immunology 5 27538750
2011 Yeast RNA viruses as indicators of exosome activity: human exosome hCsl4p participates in RNA degradation in Saccharomyces cerevisiae'. Yeast (Chichester, England) 5 22068837
2023 In vivo characterization of the critical interaction between the RNA exosome and the essential RNA helicase Mtr4 in Saccharomyces cerevisiae. G3 (Bethesda, Md.) 4 36861343
2023 Exosome complex components 1 and 2 are vital for early mammalian development. Gene expression patterns : GEP 3 37940010
2021 Detection of Melanogenesis and Anti-Apoptosis-Associated Melanoma Factors: Array CGH and PPI Mapping Integrating Study. Protein and peptide letters 3 34749602
2025 The mRNA export pathway licenses viral mimicry response and antitumor immunity by actively exporting nuclear retroelement transcripts. Science translational medicine 2 40203080
2022 Proteomic analysis of low- and high-grade human colon adenocarcinoma tissues and tissue-derived primary cell lines reveals unique biological functions of tumours and new protein biomarker candidates. Clinical proteomics 2 35842572
2024 Comparative Proteomics Identified EXOSC1 as a Target Protein of Anticancer Peptide LVTX-8 in Nasopharyngeal Carcinoma Cells. Journal of proteome research 1 38700954
2025 JAK2V617F+ single-stranded DNA modulates exosome complex activity and DNA-sensing pathways in myeloproliferative neoplasms. Molecular therapy. Nucleic acids 0 41245489
2020 Enzymatic Analysis of Reconstituted Archaeal Exosomes. Methods in molecular biology (Clifton, N.J.) 0 31768972

Missed literature

Know a paper Affinage missed for EXOSC1? Flag it for the maintainers and the community.

No submissions yet.